Dispatches
The Eternal Journal
Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.
Good Wear Score, Bad Safety: ADAC Tire Study
ADAC's tire test compilation found that the second-best wear performers failed safety checks, though ADAC says combining low wear with safety is technically feasible.
Publication on hold: evidence missing
The supplied material contains no longevity news, and the missing page content prevents verification of a connection to Microsoft's Eternal Search page.
Lilly pays Insilico $115M for AI drug discovery
Eli Lilly paid Insilico Medicine $115 million upfront for global rights to novel oral therapeutics from Insilico's AI platform; the MedCity News column names mitochondrial dysfunction among future AI drug targets, linking to the Eternal Search glossary entry.
Life Biosciences gets FDA nod for vision trial
Cofounded by Harvard geneticist David Sinclair, Life Biosciences received FDA approval for a Phase 1 gene therapy trial using partial epigenetic reprogramming in optic nerve diseases; Fortune cites CDC data on glaucoma as the second most common cause of bli...
Longevity education as a sales funnel
Ezra's longevity explainer covers life expectancy basics but cites no study linking full-body MRI screening to longer life, ending with a scan booking button.
Editorial stop: off-topic sources
Search returned results unrelated to biotech or aging research; the dispatch is withheld pending proper sources.
Google Cloud AI in biomedicine: no news yet
Available sources are AI explainer pages with no dated biomedical event, partnership, or result attributable to Google Cloud; the dispatch documents the absence and defers until a concrete primary source appears.
Smart nanoparticles for glioblastoma: illuminate and destroy
Dual-function nanoparticles illuminate hidden glioblastoma cells during brain cancer surgery and destroy microscopic tumor remnants afterward.
No dispatch: search returned irrelevant sources
Search for biomarker and longevity news returned only tech forum pages and decade-old Microsoft Office support posts with no longevity connection visible in the retrieved excerpts; post withheld.
Hinton AI-elections warning: source too thin for dispatch
An undated Wikipedia passage attributes AI election-manipulation warnings to Geoffrey Hinton but lacks the date, primary source, and study text needed to establish timeliness or write a grounded dispatch.
No source, no dispatch: ARTE and Oberstdorf
Sources collected for an ARTE dispatch contained only Oberstdorf tourism pages with no connection to aging research, so publication is withheld until a real source appears.
Two longevity pages, zero funding data
A search for longevity funding data found a TopDoctor Magazine concept article and a Healthy Longevity Clinic blog that asks how to live 10+ years beyond life expectancy, with no supporting study cited in the available text.
Roblox Requires Subscription or Fee to Publish Games
Roblox began rolling out new publishing requirements on May 19, 2026, requiring 2FA for publishing and a subscription or 1,000 Robux fee for all-ages access; available sources do not link the policy to Eternal Search investor SHiN.
Nobel Chemist Ramakrishnan Writes on Aging
Venki Ramakrishnan, 2009 Nobel laureate for ribosome structure and function, wrote a book on aging introduced by the interim director of Columbia's Aging Center, who praised its molecular precision.
Google AI lists seven focus areas but shows no funding details
Google's AI page lists seven focus areas with one-line descriptions and names products including Gemini and Project Astra, but provides no budgets, grants, or funding details.
Calico drops to #26; senolytics discussed
Calico falls from #1 to #26 in the Eternal Search company rating as the Rejuvenation Science News group discusses senolytics and cellular senescence.
Immune senescence in precision longevity medicine
ABOPM's precision longevity medicine principles span six domains including immune senescence; Intervene Immune ranks #5 in the Eternal Search company ratings at 35.4 points.
Buck Institute and Insilico Medicine form aging research collaboration
Buck Institute, the first independent biomedical research institute focused solely on aging, has formed a research collaboration with Insilico Medicine and a third unnamed institution.
Retro Bio: $180M Seed, Now Raising $1B
Retro Biosciences is raising a $1B round after Sam Altman's $180M seed, while Altos Labs holds a $3B financing commitment from investors including Bezos.
Muscle as the organ of longevity — and senescence as its threat
Healthspan's research section features an article calling skeletal muscle 'the organ of longevity' and cellular senescence its main threat — a specific claim from a commercial platform.
Senolytics Are Not Rejuvenation Proof
Senolytics have plausible biology, mouse data, and serious funding, but that is not human lifespan proof; cellular reprogramming is a separate term.
Funding is not evidence
A 2026 longevity startup watchlist is useful only if readers separate funding news from evidence and inspect what organizations like Longevity Science Foundation actually fund.
Biological Age Is Not a Verdict
Biological-age metrics are getting public attention, but these sources support research tools and protein-based signals, not a finished medical answer.
Funding First, Medicine Later
Fight Aging’s investing page is a blunt reminder that rejuvenation biotech reaches clinics through funded companies, with Repair Biotechnologies as one concrete object to inspect.
Life Biosciences: money, an IND, and no free pass
Life Biosciences is a useful longevity biotech case because it has financing and an FDA-cleared IND, not proof that aging has been reversed.
AI longevity is hiring a board
Insilico’s new Longevity Board and its AI-model tie-up are not proof of anything clinical, but they are a useful signal that longevity hype is becoming an organized industry with a visible talent network.